Minerva Neurosciences Competitors

Minerva Neurosciences (NASDAQ:NERV) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Minerva Neurosciences and Clovis Oncology, as reported by MarketBeat.

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Clovis Oncology has a consensus price target of $8.80, suggesting a potential upside of 41.71%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Clovis Oncology.

Profitability

This table compares Minerva Neurosciences and Clovis Oncology's net margins, return on equity and return on assets.

Risk & Volatility

Minerva Neurosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Minerva Neurosciences and Clovis Oncology's top-line revenue, earnings per share and valuation.

Minerva Neurosciences has higher earnings, but lower revenue than Clovis Oncology. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Minerva Neurosciences beats Clovis Oncology on 9 of the 13 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Earnings and Valuation

This table compares Minerva Neurosciences and Altimmune's top-line revenue, earnings per share and valuation.

Altimmune has higher revenue and earnings than Minerva Neurosciences. Altimmune is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 66.2% of Altimmune shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Comparatively, 2.7% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Minerva Neurosciences and Altimmune, as reported by MarketBeat.

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Altimmune has a consensus price target of $31.75, suggesting a potential upside of 91.50%. Given Minerva Neurosciences' higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Altimmune.

Risk & Volatility

Minerva Neurosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Profitability

This table compares Minerva Neurosciences and Altimmune's net margins, return on equity and return on assets.

Summary

Altimmune beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Minerva Neurosciences and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Minerva Neurosciences and Amryt Pharma, as reported by MarketBeat.

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Amryt Pharma has a consensus price target of $41.6667, suggesting a potential upside of 182.68%. Given Amryt Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Minerva Neurosciences.

Earnings & Valuation

This table compares Minerva Neurosciences and Amryt Pharma's top-line revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Minerva Neurosciences. Amryt Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amryt Pharma beats Minerva Neurosciences on 7 of the 11 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares BeyondSpring and Minerva Neurosciences' gross revenue, earnings per share and valuation.

BeyondSpring is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeyondSpring and Minerva Neurosciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

7.1% of BeyondSpring shares are owned by institutional investors. Comparatively, 66.3% of Minerva Neurosciences shares are owned by institutional investors. 12.0% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

BeyondSpring has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BeyondSpring and Minerva Neurosciences, as reported by MarketBeat.com.

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 147.85%. Minerva Neurosciences has a consensus target price of $6.75, suggesting a potential upside of 113.61%. Given BeyondSpring's stronger consensus rating and higher possible upside, research analysts plainly believe BeyondSpring is more favorable than Minerva Neurosciences.

Summary

Minerva Neurosciences beats BeyondSpring on 6 of the 11 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares Magenta Therapeutics and Minerva Neurosciences' gross revenue, earnings per share (EPS) and valuation.

Magenta Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Minerva Neurosciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Magenta Therapeutics and Minerva Neurosciences, as provided by MarketBeat.

Magenta Therapeutics presently has a consensus target price of $17.6667, suggesting a potential upside of 60.61%. Minerva Neurosciences has a consensus target price of $6.75, suggesting a potential upside of 113.61%. Given Minerva Neurosciences' higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than Magenta Therapeutics.

Institutional & Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. Comparatively, 66.3% of Minerva Neurosciences shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Comparatively, 12.0% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Magenta Therapeutics has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Summary

Minerva Neurosciences beats Magenta Therapeutics on 7 of the 11 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Minerva Neurosciences and Neoleukin Therapeutics' revenue, earnings per share and valuation.

Neoleukin Therapeutics has higher revenue and earnings than Minerva Neurosciences. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Minerva Neurosciences and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Minerva Neurosciences and Neoleukin Therapeutics, as provided by MarketBeat.

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Neoleukin Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 79.59%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Neoleukin Therapeutics.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Minerva Neurosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Neoleukin Therapeutics beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks.